Most material SEC filings — July 24, 2026

MAPFRE U.S.A. Corp agreed to acquire Safety Insurance Group Inc. via merger for $105.00 per share in cash (Merger Consideration), representing approximately $1.54 billion in total equity value. The merger is expected to close in 2027 subject to regulatory approvals and customary closing conditions. Safety Insurance shareholders will receive $105 per common share; RSA and PSA holders will receive cash equal to the merger consideration multiplied by shares subject to awards.

On July 23, 2026, Invivyd, Inc. filed an 8-K reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not provide specific details regarding which listing standard was not met, the exchange involved, timeline for cure period, or remediation plans. The company's market value is approximately $50.9M.

On July 22, 2026, FibroBiologics, Inc. received notice of delisting or failure to satisfy continued listing requirements. The 8-K filing on July 24, 2026 discloses Item 3.01 regarding notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. The specific exchange, listing standards violated, and timeline for remediation are not detailed in the filing excerpt provided.

VivoSim Labs (market cap ~$7.5M) filed a Form 8-K on 2026-07-24 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing). The filing does not disclose the specific delisting reason, the exchange involved, timeline, or any remediation plan within the document summary provided. This represents a fundamental loss of public market status.

GoPro filed an 8-K on July 24, 2026 (Item 3.01) reporting notice of delisting or failure to satisfy continued listing rules/standards. The filing does not specify which exchange, exact non-compliance reason, or remediation timeline. This represents an existential threat to a ~$99.5M market-cap company.

On July 21, 2026, Arrive AI Inc. (market cap ~$99M) received notification of failure to satisfy continued listing standards. The filing indicates Item 3.01 reporting (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard). No specific cure period, specific violation details, or remediation plan are disclosed in this 8-K excerpt.

On July 20, 2026, Liminatus Pharma received notice of delisting or failure to satisfy continued listing rules/standards, with transfer of listing noted. The filing provides no specific details on the reason for delisting notice, the exchange involved, cure period, or remedial actions. The 8-K discloses the event under Items 3.01 and 8.01 but contains no quantified financial impact or timeline.

On July 24, 2026, Fusemachines Inc. (a $4.9M-asset company) filed an 8-K reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing provides no specific details on which listing rule was violated, remediation steps, or timeline for cure, only that a delisting notice was received.

On July 24, 2026, the FDA approved LYTENAVA (bevacizumab-vikg), making it the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD treatment. The approval grants 12 years of market exclusivity under BPCIA. Outlook targets the ~$8.5 billion U.S. retina anti-VEGF market and plans commercial launch with patient availability before year-end 2026.

INVO Fertility (public market cap ~$2.2M) entered an Any Market Purchase Agreement with Alumni Capital LP on July 24, 2026, establishing a $15M commitment (expandable to $50M) for the purchase of common shares at 85-97% of market price, with Alumni Capital receiving 1% commitment fee in stock or cash. Company must register all shares within 120 days. No specific dollar amount or share count has closed yet; this is a commitment structure with future draws at company's discretion.

On July 20, 2026, Peraso Inc. received notice of delisting or failure to satisfy continued listing standards (Item 3.01), triggering shareholder nomination procedures under Exchange Act Rule 14a-11 (Item 5.08). The filing provides no dollar amounts, counterparties, or specific remediation details. The company (market cap ~$6.3M) faces potential exchange delisting, which is a critical threat to its continued public status.

Quantum-Si Inc filed an 8-K on 2026-07-24 disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing itself contains no specific dollar amounts, counterparty names, share counts, or detailed explanation of which listing standard was violated or what remedial actions are planned. The substantive terms and conditions of any transfer are not disclosed in the header documents provided.

On July 21, 2026, LiqTech International Inc. (market cap ~$9.7M) received notice of failure to satisfy continued listing standards. The filing is a Form 8-K Item 3.01 reporting delisting or listing rule failure; specific technical violations, remediation plans, or timelines are not disclosed in the header materials provided.

Digital Brands Group issued a $3,529,412 principal convertible promissory note (with $529,412 original issue discount) to accredited investors on July 23, 2026, with payments due Oct-Jan 2027. Concurrently, the company entered into a $100M equity line of credit (ELOC) agreement. The note converts on default at 90% of 5-day VWAP or a floor price (initially $0.09898), with extensive anti-dilution and prepayment obligations tied to future fundraising proceeds.

On June 9, 2026, Jaguar Health (market cap ~$3.8M) entered into an equity line of credit (ELOC) with C/M Capital Master Fund, LP, committing to purchase up to $40 million of common stock at the company's discretion. The company also issued $800,000 of Commitment Shares upfront and $2.0 million of Series P Preferred Stock to investors including C/M Capital. Up to 41 million common shares are registered for resale (89.3% of current shares outstanding as of July 10, 2026). The structure includes Fixed Purchases, VWAP Purchases, and Additional VWAP Purchases at market-linked prices (minimum 5% discount), subject to a $1.10 floor price and 4.99% beneficial ownership cap.

On July 24, 2026, Chegg received notice from NYSE that its average closing share price fell below $1.00 over 30 consecutive trading days ending July 23, 2026, violating Section 802.01C of the NYSE Listed Company Manual. This is the second such notice in eight months (first in December 2025, cured by May 2026). Chegg has six months to regain compliance or face delisting; the company may pursue a reverse stock split if necessary.

On July 21, 2026, Odyssey Marine Exploration received notice of delisting or failure to satisfy continued listing standards (Item 3.01). No specific exchange, rule violated, remediation timeline, or financial metrics are detailed in the filing header. The company must respond to exchange requirements to maintain public listing status.

NaaS Technology Inc. agreed to acquire 100% of China Newlink Holding Limited (held by Newlink Digital Energy Holding Limited) for US$15,000,000, payable entirely in newly issued Class A Ordinary Shares: 16,000,000,000 shares (5,000,000 ADSs at US$3.00/ADS reference price). The transaction is a related-party deal involving Newlinks Technology Limited (NaaS's controlling shareholder) and multiple Newlink-affiliated entities. Closing is contingent on Nasdaq approval, SEC filing, Audit Committee approval, VIE restructuring, regulatory clearances, and due diligence satisfaction; long-stop date is December 31, 2026. The seller bears all reorganization costs and indemnifies against pre-closing liabilities.

On July 22, 2026, Standard Biotools Inc. received notice of failure to satisfy continued listing standards, triggering Item 3.01 delisting disclosure. The filing provides notice of the delisting or transfer of listing event but does not specify the particular listing rule violated, remediation timeline, or whether the company will seek to regain compliance or transfer exchanges.

On July 20, 2026, Oncolytics Biotech received a notice of delisting or failure to satisfy continued listing standards from its exchange. The 8-K filed July 24, 2026 discloses Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), but the filing provides no details on the specific rule violated, timeline for cure, or remediation plan. No counterparties, dollar amounts, or concrete remediation details are disclosed in the available filing text.

10% owner Blackstone Private Multi-Asset Credit & Income Fund (NONE) bought 574K shares (~$15.0M) on the open market (6.4% of holdings). Open-market insider purchase — historically a bullish signal.

On July 10, 2026, Cycurion received a Nasdaq delisting determination for failure to meet minimum bid price requirement under Listing Rule 5550(a)(1). The company requested and scheduled a hearing before the Nasdaq Hearings Panel for August 2026. The hearing request has stayed delisting pending the panel's decision; stock continues trading on Nasdaq Capital Market under symbol CYCU.

10% owner DART KENNETH BRYAN (FLUT) bought 306K shares (~$30.4M) on the open market (1.6% of holdings). Open-market insider purchase — historically a bullish signal.

MRC Ranger LLC (Matador subsidiary) agreed to acquire 100% of Paloma Permian LLC for $1,275,000,000 (unadjusted), effective June 1, 2026, with closing targeted shortly. Deal includes oil and gas properties (leases, wells, surface rights) across four New Mexico asset areas (Arrowhead, Ranger, Antelope Ridge, Rustler Breaks) with multiple geological formations. Purchase price subject to working capital, defect/title adjustments, and post-closing true-up through established escrow and arbitration procedures.

Galaxy Digital's subsidiary Galaxy Helios Data Centers II LLC priced a $3.507 billion offering of 9.875% senior secured notes due 2031, closing expected July 28, 2026. Net proceeds will finance development of two buildings with 400 MW utility capacity and 260 MW critical IT capacity in Dickens County, Texas, plus debt service reserves. Notes amortize at 4% annually starting at least ten months post-project completion.

Quantum Cyber N.V. (market cap ~$5.7M) acquired a ~50,000 sq ft manufacturing facility in Bridgeport, Connecticut on July 15, 2026 for $2.3M and assumed ~$2.09M in open purchase orders. On June 11, 2026, the company signed an exclusive worldwide license to Project LightShift's quantum photonic array technology for autonomous defense systems. The company previously raised ~$15M via warrant exercises (May 2026), retired all debt, terminated its ATM facility, and rebranded from MYNZ to QUCY (March 2026). Core products include autonomous drones (SWARM-X, FALCON 55), ground vehicles (GUARDIAN-X), and maritime USVs, with signed letters of intent from General Cherry and SOCOM.

NextEra Energy reported Q2 2026 adjusted EPS of $1.15 (up 9.5% YoY) and Q2 GAAP net income of $3.144 billion ($1.50/share). On July 15–23, 2026, NextEra and Dominion Energy filed merger applications with Virginia, North Carolina, South Carolina, FERC, NRC, and SEC; the S-4 registration became effective July 23. The deal includes $2.25 billion in customer bill credits and targets 11% annual regulatory capital growth and 9%+ adjusted EPS growth through 2032 (off 2025 base). FPL grew regulatory capital 9.3% YoY; NextEra Resources added 3.6 GW renewables/storage backlog (35.1 GW total). Expected close: H2 2027. NextEra reaffirms 2026 adjusted EPS guidance of $3.92–$4.02 and 8%+ CAGR through 2035.

American Resources Corp filed an 8-K on 2026-07-24 reporting Item 4.01 (Changes in Registrant's Certifying Accountant) and Item 4.02 (Non-Reliance on Previously Issued Financial Statements). The filing discloses a change in auditor and indicates the company is restating previously issued financial statements as of 2026-06-30. Specific details regarding the prior auditor, new auditor identity, reason for change, and nature/magnitude of restatement are not provided in this header document.

NewAmsterdam Pharma and Menarini Group received a positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending European marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (obicetrapib 10 mg plus ezetimibe 10 mg fixed-dose combination) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM trial data showing 40% LDL-C reduction with monotherapy and 50% with combination versus placebo. European Commission final decision expected in H2 2026; NewAmsterdam is entitled to tiered double-digit to mid-twenties percentage royalties on net sales and up to €833 million in milestone payments.

Berkshire Hathaway completed its acquisition of Taylor Morrison Home Corp on July 23, 2026, for $72.50/share in cash, representing ~$6.8B equity value and ~$8.5B enterprise value (including debt assumption). The deal, announced May 31, 2026, makes Taylor Morrison a wholly-owned subsidiary. Concurrent with closing, Taylor Morrison amended its credit agreement (Wells Fargo admin agent; lenders include Bank of America, JPMorgan, Goldman Sachs, Mizuho, U.S. Bank, PNC, Truist, Regions, Nova Scotia, Zions) to consent to the change-of-control and modified covenant definitions to reflect Berkshire as "Permitted Holder." Three senior note indentures (2028, 2030, 2032 due dates) were amended to relax reporting and merger-covenant requirements upon Berkshire guarantee.

TEN Holdings filed an 8-K on 2026-07-24 reporting termination of a material definitive agreement (Item 1.02) and departure of director(s) or officer(s) with compensatory arrangements (Item 5.02) as of 2026-07-20. The filing does not disclose specific counterparties, dollar amounts, dates of agreement execution, or names of departing officers—only that these events occurred.

Vera Bradley executed Executive Severance Plan Agreements effective July 24, 2026, with Martin Layding (CEO & Chairman) and Melinda Paraie. Layding receives 12 months base salary + 6 months in Change in Control scenario, plus full vesting of 414,439 RSUs granted June 12, 2025, plus pro-rata vesting of other RSUs through fiscal 2028. Paraie receives identical severance structure with full vesting of 269,231 RSUs granted December 12, 2025, plus pro-rata vesting of other RSUs through fiscal 2028. Both agreements include 12-month non-compete, non-solicitation, confidentiality, and non-disparagement covenants. Terms run through March 31, 2029, with auto-renewal. Combined RSU grants: ~683,670 shares.

On 2026-07-21, Interactive Strength, Inc. entered into a material definitive agreement (Item 1.01), created a direct financial obligation (Item 2.03), and conducted an unregistered sale of equity securities (Item 3.02). The filing does not disclose the counterparty name, dollar amounts, share counts, terms, or any concrete details of these transactions.

Ramaco Resources raised $200M in equity (underwritten by Morgan Stanley and Goldman Sachs) and secured a term sheet from KeyBank to expand its revolving credit facility from $200M to $400M (with $150M accordion feature). The company's Board authorized expansion of the Brook Mine from 2 million tons to 5 million tons annual coal production, increasing rare earth oxide output from 1,240 to ~3,400 tons per year, with potential to reach 8-10 million tons depending on demand. A revised mine plan targets higher cut-off grades (500 ppm), and the company retained Hatch Ltd. to deliver a Pre-Feasibility Study by Q1 2026, with pilot plant operations expected later in 2025 and commercial oxide plant construction beginning late 2026.

Consumer Portfolio Services closed its largest securitization ever on July 22, 2026: $716.88M in asset-backed notes (issued by CPS Auto Receivables Trust 2026-C) secured by $734.51M in auto receivables. The five-class transaction received AAA ratings from both S&P and DBRS Morningstar on its senior class (Class A: $317.3M at 4.52%), with weighted-average coupon of 5.90%. This is CPS's 60th securitization since 2011 and its 43rd consecutive to achieve dual AAA ratings, demonstrating continued capital market access and credit quality.

Matinas BioPharma (market cap ~$4.5M) filed an 8-K on July 24, 2026 reporting termination of a material definitive agreement effective July 23, 2026. The filing does not disclose the identity of the counterparty, the nature of the agreement, financial terms, or reasons for termination—only that Item 1.02 was triggered.

On July 22, 2026, Mahmud Haq (individually and through two family trusts) pledged 4,300,000 shares of CareCloud common stock to Citizens Bank, N.A. as collateral for a credit facility entered into in April 2026. Haq simultaneously received a warrant to purchase 4,300,000 additional shares at $5.00/share, vesting over 12 months (July 2026–June 2027). The pledge is secured by three accounts totaling those 4.3M shares (1.894M personal, 1.203M per trust each), with Citizens Securities as intermediary holding control. The pledge terminates upon full repayment or when leverage ratio drops below 1.25× within 2 years.

On July 24, 2026, INVO Fertility (public market cap ~$2.2M) entered an Any Market Purchase Agreement with Alumni Capital LP permitting INVO to sell up to 20,000,000 shares (representing ~89.7% of current outstanding shares if all issued) for up to $15M gross proceeds (expandable to $50M by mutual agreement). Alumni will resell shares at market prices; INVO receives no proceeds from Alumni's resales. INVO pays 1% commitment fee and controls timing/amount of sales to Alumni. Additionally, INVO completed acquisition of HRCFG (Birmingham fertility clinic) for $175,001 ($1 cash at closing, $48K over 9 months, $127K from free cash flow) on June 23, 2026.

On July 24, 2026, Surf Air Mobility received notice from NYSE that its average closing stock price fell below $1.00 over a consecutive 30 trading-day period, violating Section 802.01C of the NYSE Listed Company Manual. The company has a 6-month cure period and may regain compliance by achieving a closing price and 30-day average of at least $1.00 per share, either organically or via reverse stock split (previously approved by shareholders on July 24, 2026). No immediate delisting impact; continued listing contingent on compliance with other NYSE standards.

Check-Cap Ltd (Israeli medical-device company, $7.5M assets) is merging with MBody AI Corp (robotics/AI software, Las Vegas). Upon closing: Check-Cap shareholders own ~10%, MBody AI shareholders own ~90% on fully diluted basis. Merger contingent on Nasdaq approval; expected H2 2026. Separately, ~$16.3M in Apollo Loans will be exchanged for 7.5% equity stake in Apollo, but only if Merger closes—if Merger fails, loans remain outstanding with going-concern doubts.

Onfolio Holdings filed an 8-K on 2026-07-27 reporting termination of a material definitive agreement as of 2026-07-21 (Item 1.02). The filing provides no specifics: no counterparty name, dollar amounts, financial terms, effective date details, or reasons for termination are disclosed in the available text. Only boilerplate XBRL exhibits are present.

Chief Banking Officer MCCABE ROBERT A JR (PNFP) bought 10K shares (~$1.0M) on the open market (3.0% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Opaleye Management Inc. (ACOG) bought 200K shares (~$1.6M) on the open market (6.3% of holdings). Open-market insider purchase — historically a bullish signal.

Director Perry-Smith Robert Truxtun (FSBC) bought 31K shares (~$1.4M) on the open market (11% of holdings). Open-market insider purchase — historically a bullish signal.

Director Allbaugh Larry Eugene (FSBC) bought 97K shares (~$4.3M) on the open market (8.1% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner PASQUESI JOHN M (CLIR) bought 500K shares (~$1.8M) on the open market (27% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner ASSURED GUARANTY LTD (NONE) bought 209K shares (~$5.2M) on the open market (15% of holdings). Open-market insider purchase — historically a bullish signal.

Surgery Partners agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The combined facilities are valued at ~$1.15B, with Surgery Partners receiving ~$795M in total consideration. The transaction is subject to physician approval, regulatory clearance (Hart-Scott-Rodino), and customary closing conditions; expected to close in coming months. Company reaffirms 2026 guidance of $3.35–$3.45B revenue and ≥$530M Adjusted EBITDA excluding transaction impact.

Profound Medical announced positive interim data from the CAPTAIN Level 1 randomized controlled trial comparing its TULSA-PRO system to robotic radical prostatectomy for intermediate-risk prostate cancer (Gleason 7). At 1 month, TULSA patients showed no median penile length change versus 0.65 cm reduction in robotic RP (p<0.001); TULSA previously demonstrated statistically significant superiority in erectile function and urinary continence preservation at 6 months. The trial enrolled 211 patients across 23 sites by August 2025, exceeding the planned 201-patient target.

Limbach Facility Services LLC increased its revolving credit facility from $100M to $125M with Wheaton Bank Trust Company (dated July 24, 2026). Lenders consented to the company's acquisition of CYMCOR, Inc. for total consideration exceeding $25M—a deal that previously exceeded the $25M acquisition cap. The amendment also adjusted pricing margins tied to senior leverage ratio tiers and modified use-of-proceeds language.